Abcellera Biologics Inc (ABCL)

$3.56 -0.09 (-2.47%)
Market Cap 1.07B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 2,295,900
Avg Vol 5,246,802
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 39%
Beta 0.73
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
UncleTomFlorida
UncleTomFlorida Dec. 7 at 2:40 PM
$ABCL Timewise, this is a period for accumulation pending successful certification of current trials. As with all pharma, this is a risky gamble. That said , the long term rewards are potentially infinite, given the science and business models.
0 · Reply
BstnGeorge
BstnGeorge Dec. 6 at 2:32 PM
$ABCL
1 · Reply
Plutten1973
Plutten1973 Dec. 5 at 6:32 PM
$ABCL Normal Abcellera day Cheers everyone, Happy friday !
1 · Reply
Ed_Ng
Ed_Ng Dec. 5 at 5:02 PM
$ABCL see guys. All bagholders disappear today!
0 · Reply
Ed_Ng
Ed_Ng Dec. 5 at 2:49 PM
$ABCL hahaha. Thank you.
0 · Reply
Ed_Ng
Ed_Ng Dec. 5 at 2:48 PM
$ABCL yes. 2$
0 · Reply
bonecrack_benny
bonecrack_benny Dec. 5 at 6:55 AM
$ABCL Will probably never go down bewlow 3-3.50 again. Target 10 before H2 2026. Night even happen during Q1.
0 · Reply
Odoji
Odoji Dec. 5 at 6:53 AM
$ABCL
0 · Reply
iTrade_Price
iTrade_Price Dec. 5 at 2:49 AM
$ABCL - abcl
1 · Reply
RonnieVTrades
RonnieVTrades Dec. 4 at 11:19 PM
$ABCL Oversold and starting to show bottoming signs...
0 · Reply
Latest News on ABCL
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 15 days ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 27 days ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 4 weeks ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 2 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 3 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 3 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 4 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 4 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Jun 2, 2025, 6:45 PM EDT - 6 months ago

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 7 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 7 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 7 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 7 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 9 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 10 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 11 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 11 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Jul 21, 2024, 5:37 AM EDT - 1 year ago

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

FATE

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Down 57%, Is AbCellera Biologics a Buy on the Dip?

Jun 13, 2024, 5:40 AM EDT - 1 year ago

Down 57%, Is AbCellera Biologics a Buy on the Dip?

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

UncleTomFlorida
UncleTomFlorida Dec. 7 at 2:40 PM
$ABCL Timewise, this is a period for accumulation pending successful certification of current trials. As with all pharma, this is a risky gamble. That said , the long term rewards are potentially infinite, given the science and business models.
0 · Reply
BstnGeorge
BstnGeorge Dec. 6 at 2:32 PM
$ABCL
1 · Reply
Plutten1973
Plutten1973 Dec. 5 at 6:32 PM
$ABCL Normal Abcellera day Cheers everyone, Happy friday !
1 · Reply
Ed_Ng
Ed_Ng Dec. 5 at 5:02 PM
$ABCL see guys. All bagholders disappear today!
0 · Reply
Ed_Ng
Ed_Ng Dec. 5 at 2:49 PM
$ABCL hahaha. Thank you.
0 · Reply
Ed_Ng
Ed_Ng Dec. 5 at 2:48 PM
$ABCL yes. 2$
0 · Reply
bonecrack_benny
bonecrack_benny Dec. 5 at 6:55 AM
$ABCL Will probably never go down bewlow 3-3.50 again. Target 10 before H2 2026. Night even happen during Q1.
0 · Reply
Odoji
Odoji Dec. 5 at 6:53 AM
$ABCL
0 · Reply
iTrade_Price
iTrade_Price Dec. 5 at 2:49 AM
$ABCL - abcl
1 · Reply
RonnieVTrades
RonnieVTrades Dec. 4 at 11:19 PM
$ABCL Oversold and starting to show bottoming signs...
0 · Reply
Ed_Ng
Ed_Ng Dec. 4 at 8:09 PM
$ABCL I knew it. Up 6% after 50% down and now lots of bagholders come out and said like it's up 600% 😂. 2$ is the target, it's not going anywhere
0 · Reply
OnChainAce
OnChainAce Dec. 4 at 6:43 PM
$ABCL A rally is right around the corner👀
1 · Reply
Cassek86
Cassek86 Dec. 4 at 5:53 PM
$ABCL Good luck!
1 · Reply
TheDrunkTrader69
TheDrunkTrader69 Dec. 4 at 4:35 PM
$ABCL Hmmm smells spicy
0 · Reply
DOGBIRD
DOGBIRD Dec. 4 at 3:40 PM
$ABCL Will it break above that 400sma on 15m chart? couldn't break it twice in November.
1 · Reply
SophiaBreez
SophiaBreez Dec. 4 at 10:26 AM
$ABCL on watch
0 · Reply
SophiaBreez
SophiaBreez Dec. 4 at 10:25 AM
$ABCL
0 · Reply
HedgeAlerts
HedgeAlerts Dec. 4 at 7:11 AM
Hedge Alert Live - Protect Your Portfolio Contract: $ABCL $3.00 Put · DEC 19, 2025 Exp Entry Price: $0.05 - $0.15 Exit Price Target: $0.10 Profit Margin: +104% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Kaykay610
Kaykay610 Dec. 3 at 10:55 PM
$ABCL I've been reviewing bruker vs abcellera and abcellera's case looks strong!!! Next catalyst is bruker case results or licensing settlement. Jan 26 2026.
2 · Reply
DOGBIRD
DOGBIRD Dec. 3 at 8:53 PM
$ABCL Willing to buy at higher SP mid next year after data.
0 · Reply
Samb2344
Samb2344 Dec. 3 at 7:09 PM
$ABCL 🤌
0 · Reply
Ed_Ng
Ed_Ng Dec. 3 at 6:58 PM
$ABCL easy short ever!
0 · Reply